Research ExplorerPublicationsAberrant expression of membranous carbonic anhydrase IX (CAI...

Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma

Standard

Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. / Büscheck, Franziska; Fraune, Christoph; Simon, Ronald; Kluth, Martina; Hube-Magg, Claudia; Möller-Koop, Christina; Shadanpour, Navid; Bannenberg, Clemens; Eichelberg, Christian; Höflmayer, Doris; Clauditz, Till; Wittmer, Corinna; Wilczak, Waldemar; Sauter, Guido; Fisch, Margit; Rink, Michael; Eichenauer, Till.

In: UROL ONCOL-SEMIN ORI, Vol. 36, No. 12, 12.2018, p. 531.e19-531.e25.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Büscheck, F, Fraune, C, Simon, R, Kluth, M, Hube-Magg, C, Möller-Koop, C, Shadanpour, N, Bannenberg, C, Eichelberg, C, Höflmayer, D, Clauditz, T, Wittmer, C, Wilczak, W, Sauter, G, Fisch, M, Rink, M & Eichenauer, T 2018, 'Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma', UROL ONCOL-SEMIN ORI, vol. 36, no. 12, pp. 531.e19-531.e25. https://doi.org/10.1016/j.urolonc.2018.08.015

APA

Büscheck, F., Fraune, C., Simon, R., Kluth, M., Hube-Magg, C., Möller-Koop, C., Shadanpour, N., Bannenberg, C., Eichelberg, C., Höflmayer, D., Clauditz, T., Wittmer, C., Wilczak, W., Sauter, G., Fisch, M., Rink, M., & Eichenauer, T. (2018). Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. UROL ONCOL-SEMIN ORI, 36(12), 531.e19-531.e25. https://doi.org/10.1016/j.urolonc.2018.08.015

Vancouver

Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C et al. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. UROL ONCOL-SEMIN ORI. 2018 Dec;36(12):531.e19-531.e25. https://doi.org/10.1016/j.urolonc.2018.08.015

Bibtex

@article{a058eb606b284e76bb88b43da9a9241c,
title = "Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma",
abstract = "OBJECTIVE: Antibodies against carbonic anhydrase IX (CAIX) are often part of immunohistochemical panels used to assist renal cell cancer (RCC) subtyping. This study was undertaken to determine, whether assessing CAIX expression levels could provide additional prognostic information.METHODS AND MATERIALS: More than 1,800 RCCs were analyzed in a tissue microarray (TMA) format for CAIX expression. All tumors had been reviewed and newly classified according to the WHO 2016 classification.RESULTS: Membranous CAIX expression revealed a {"}black and white{"} pattern that was strikingly dependent on the RCC subtype. In clear cell RCC, 89.2% of cancers showed strong positivity. The few clear cell RCC with lower CAIX expression levels were more likely to exhibit unfavorable tumor phenotype (p < 0.0001) and poor disease course (p = 0.0036). CAIX was completely absent in 99% of chromophobe RCC and in 100% of oncocytomas. In papillary RCC, 80.2% of cancers showed complete absence of CAIX staining. Papillary RCC with detectable CAIX expression had a less favorable tumor phenotype (p≤0.05) and worse disease outcome (p = 0.0176). These data are consistent with the concept, that {"}aberrant{"} CAIX staining - meaning absent or weak staining in a cancer expected to have a high level CAIX expression such as clear cell RCC or detectable CAIX expression in tumors that are typically CAIX negative such as papillary and chromophobe RCC - reflects biologic tumor dedifferentiation.CONCLUSION: Our data demonstrate that CAIX is a highly useful diagnostic biomarker for RCC providing both diagnostic and prognostic information.",
keywords = "Journal Article",
author = "Franziska B{\"u}scheck and Christoph Fraune and Ronald Simon and Martina Kluth and Claudia Hube-Magg and Christina M{\"o}ller-Koop and Navid Shadanpour and Clemens Bannenberg and Christian Eichelberg and Doris H{\"o}flmayer and Till Clauditz and Corinna Wittmer and Waldemar Wilczak and Guido Sauter and Margit Fisch and Michael Rink and Till Eichenauer",
note = "Copyright {\textcopyright} 2018 Elsevier Inc. All rights reserved.",
year = "2018",
month = dec,
doi = "10.1016/j.urolonc.2018.08.015",
language = "English",
volume = "36",
pages = "531.e19--531.e25",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma

AU - Büscheck, Franziska

AU - Fraune, Christoph

AU - Simon, Ronald

AU - Kluth, Martina

AU - Hube-Magg, Claudia

AU - Möller-Koop, Christina

AU - Shadanpour, Navid

AU - Bannenberg, Clemens

AU - Eichelberg, Christian

AU - Höflmayer, Doris

AU - Clauditz, Till

AU - Wittmer, Corinna

AU - Wilczak, Waldemar

AU - Sauter, Guido

AU - Fisch, Margit

AU - Rink, Michael

AU - Eichenauer, Till

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2018/12

Y1 - 2018/12

N2 - OBJECTIVE: Antibodies against carbonic anhydrase IX (CAIX) are often part of immunohistochemical panels used to assist renal cell cancer (RCC) subtyping. This study was undertaken to determine, whether assessing CAIX expression levels could provide additional prognostic information.METHODS AND MATERIALS: More than 1,800 RCCs were analyzed in a tissue microarray (TMA) format for CAIX expression. All tumors had been reviewed and newly classified according to the WHO 2016 classification.RESULTS: Membranous CAIX expression revealed a "black and white" pattern that was strikingly dependent on the RCC subtype. In clear cell RCC, 89.2% of cancers showed strong positivity. The few clear cell RCC with lower CAIX expression levels were more likely to exhibit unfavorable tumor phenotype (p < 0.0001) and poor disease course (p = 0.0036). CAIX was completely absent in 99% of chromophobe RCC and in 100% of oncocytomas. In papillary RCC, 80.2% of cancers showed complete absence of CAIX staining. Papillary RCC with detectable CAIX expression had a less favorable tumor phenotype (p≤0.05) and worse disease outcome (p = 0.0176). These data are consistent with the concept, that "aberrant" CAIX staining - meaning absent or weak staining in a cancer expected to have a high level CAIX expression such as clear cell RCC or detectable CAIX expression in tumors that are typically CAIX negative such as papillary and chromophobe RCC - reflects biologic tumor dedifferentiation.CONCLUSION: Our data demonstrate that CAIX is a highly useful diagnostic biomarker for RCC providing both diagnostic and prognostic information.

AB - OBJECTIVE: Antibodies against carbonic anhydrase IX (CAIX) are often part of immunohistochemical panels used to assist renal cell cancer (RCC) subtyping. This study was undertaken to determine, whether assessing CAIX expression levels could provide additional prognostic information.METHODS AND MATERIALS: More than 1,800 RCCs were analyzed in a tissue microarray (TMA) format for CAIX expression. All tumors had been reviewed and newly classified according to the WHO 2016 classification.RESULTS: Membranous CAIX expression revealed a "black and white" pattern that was strikingly dependent on the RCC subtype. In clear cell RCC, 89.2% of cancers showed strong positivity. The few clear cell RCC with lower CAIX expression levels were more likely to exhibit unfavorable tumor phenotype (p < 0.0001) and poor disease course (p = 0.0036). CAIX was completely absent in 99% of chromophobe RCC and in 100% of oncocytomas. In papillary RCC, 80.2% of cancers showed complete absence of CAIX staining. Papillary RCC with detectable CAIX expression had a less favorable tumor phenotype (p≤0.05) and worse disease outcome (p = 0.0176). These data are consistent with the concept, that "aberrant" CAIX staining - meaning absent or weak staining in a cancer expected to have a high level CAIX expression such as clear cell RCC or detectable CAIX expression in tumors that are typically CAIX negative such as papillary and chromophobe RCC - reflects biologic tumor dedifferentiation.CONCLUSION: Our data demonstrate that CAIX is a highly useful diagnostic biomarker for RCC providing both diagnostic and prognostic information.

KW - Journal Article

U2 - 10.1016/j.urolonc.2018.08.015

DO - 10.1016/j.urolonc.2018.08.015

M3 - SCORING: Journal article

C2 - 30322727

VL - 36

SP - 531.e19-531.e25

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 12

ER -